Literature DB >> 3551831

Entry of ketoconazole into Candida albicans.

P Boiron, E Drouhet, B Dupont, L Improvisi.   

Abstract

To define characteristics that determine the entry of ketoconazole (KTZ) into Candida albicans cells, we studied the uptake of [3H]KTZ. The cells rapidly and markedly concentrated the drug: 30% of the final 80-fold intracellular concentration was attained in less than 1 min, and greater than 60% was attained in 10 min. Penetration of [3H]KTZ at an extracellular concentration higher than 0.1875 microM (0.1 microgram/ml) occurred by a simple diffusion mechanism. At lower concentrations, accumulation of the drug was an active, energy-requiring process, dependent at least in part on glycolysis, and pH dependent (optimal pH, 6.6). The active transport system had a high binding affinity (Km = 50 nM) and a high maximum velocity of uptake (Vmax = 1.4 mumol min-1 10(-7) cells). It was not possible to displace intracellular [3H]KTZ with high concentrations of unlabeled KTZ or other antifungal agents. These findings suggest that KTZ is rapidly taken up, highly concentrated, and tightly bound to cellular components of C. albicans.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3551831      PMCID: PMC174699          DOI: 10.1128/AAC.31.2.244

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  In vitro studies of amphotericin B in combination with the imidazole antifungal compounds clotrimazole and miconazole.

Authors:  R F Cosgrove; A E Beezer; R J Miles
Journal:  J Infect Dis       Date:  1978-11       Impact factor: 5.226

2.  Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms.

Authors:  G Medoff; M Comfort; G S Kobayashi
Journal:  Proc Soc Exp Biol Med       Date:  1971-11

3.  Direct membrane-damaging effect of ketoconazole and tioconazole on Candida albicans demonstrated by bioluminescent assay of ATP.

Authors:  S Anséhn; L Nilsson
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

4.  In vitro synergy and antagonism of antifungal agents against yeast-like fungi.

Authors:  B Dupont; E Drouhet
Journal:  Postgrad Med J       Date:  1979-09       Impact factor: 2.401

5.  Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles and triazoles.

Authors:  H Van den Bossche; G Willemsens; W Cools; P Marichal; W Lauwers
Journal:  Biochem Soc Trans       Date:  1983-12       Impact factor: 5.407

6.  Letter: Antagonism between miconazole and amphotericin B.

Authors:  L P Schacter; R J Owellen; H K Rathbun; B Buchanan
Journal:  Lancet       Date:  1976-08-07       Impact factor: 79.321

7.  Synergistic action of amphotericin B and rifampin against Candida species.

Authors:  W H Beggs; G A Sarosi; M I Walker
Journal:  J Infect Dis       Date:  1976-02       Impact factor: 5.226

8.  Laboratory and clinical assessment of ketoconazole in deep-seated mycoses.

Authors:  E Drouhet; B Dupont
Journal:  Am J Med       Date:  1983-01-24       Impact factor: 4.965

9.  Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole.

Authors:  J R Graybill; D M Williams; E Van Cutsem; D J Drutz
Journal:  Rev Infect Dis       Date:  1980 Jul-Aug

10.  Comparison of the in vitro antifungal activities of miconazole and a new imidazole, R41,400.

Authors:  D Dixon; S Shadomy; H J Shadomy; A Espinel-Ingroff; T M Kerkering
Journal:  J Infect Dis       Date:  1978-08       Impact factor: 5.226

View more
  9 in total

1.  Protonation of ketoconazole in relation to fungistatic activity.

Authors:  W H Beggs
Journal:  Mycopathologia       Date:  1991-10       Impact factor: 2.574

Review 2.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

3.  Inactivation of the FCY2 gene encoding purine-cytosine permease promotes cross-resistance to flucytosine and fluconazole in Candida lusitaniae.

Authors:  Florence Chapeland-Leclerc; Julien Bouchoux; Abdelhak Goumar; Christiane Chastin; Jean Villard; Thierry Noël
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance.

Authors:  G D Albertson; M Niimi; R D Cannon; H F Jenkinson
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

5.  Flucytosine-fluconazole cross-resistance in purine-cytosine permease-deficient Candida lusitaniae clinical isolates: indirect evidence of a fluconazole uptake transporter.

Authors:  Thierry Noël; Fabienne François; Patrick Paumard; Christiane Chastin; Daniel Brèthes; Jean Villard
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

6.  Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata.

Authors:  T Parkinson; D J Falconer; C A Hitchcock
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

7.  Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi.

Authors:  Bryce E Mansfield; Hanna N Oltean; Brian G Oliver; Samantha J Hoot; Sarah E Leyde; Lizbeth Hedstrom; Theodore C White
Journal:  PLoS Pathog       Date:  2010-09-30       Impact factor: 6.823

8.  Accumulation of an antidepressant in vesiculogenic membranes of yeast cells triggers autophagy.

Authors:  Jingqiu Chen; Daniel Korostyshevsky; Sean Lee; Ethan O Perlstein
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

9.  Combining Colistin and Fluconazole Synergistically Increases Fungal Membrane Permeability and Antifungal Cidality.

Authors:  Maayan Bibi; Sarah Murphy; Raphael I Benhamou; Alex Rosenberg; Adi Ulman; Tihana Bicanic; Micha Fridman; Judith Berman
Journal:  ACS Infect Dis       Date:  2021-01-20       Impact factor: 5.084

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.